Published in Scand J Immunol on May 01, 1984
The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes. Proc Natl Acad Sci U S A (2008) 1.15
The acetylcholine receptor. I. Purification and characterization of a macromolecule isolated from Electrophorus electricus. J Biol Chem (1973) 1.75
Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry (1978) 1.68
Acetylcholine receptor and myasthenia gravis. Ann N Y Acad Sci (1976) 1.54
Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. J Intern Med (1995) 1.51
Induction of T-cell activation by oxidized low density lipoprotein. Arterioscler Thromb (1992) 1.46
Characterization of the expanded T-cell populations in patients with Wegener's granulomatosis. J Intern Med (2006) 1.46
Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-referent study nested within the MONICA and Västerbotten cohort project. Stroke (2000) 1.43
Proteinuria and renal function in relation to renal morphology. A clinicopathological study of IgA nephropathy at the time of kidney biopsy. Clin Nephrol (1992) 1.41
LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol (2001) 1.39
Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol (1995) 1.32
A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein. Genes Immun (2002) 1.32
Acetylcholine receptor. Responses to drug binding. J Biol Chem (1977) 1.29
A radioimmunoassay for the quantitative evaluation of anti-human acetylcholine receptor antibodies in myasthenia gravis. Clin Exp Immunol (1977) 1.23
Acetylcholine receptor antibody in myasthenia gravis: purification and characterization. Scand J Immunol (1978) 1.19
Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia (1987) 1.18
IgG production within the central nervous system: a critical review of proposed formulae. Ann Neurol (1985) 1.17
Anti-idiotypic antibodies against the receptor antibodies in myasthenia gravis. Scand J Immunol (1981) 1.10
Immunoglobulins in myasthenia gravis: effect of human lymph IgG 3 and F (ab')2 fragments on a cholinergic receptor preparation from Torpedo marmorata. Eur J Clin Invest (1977) 1.10
Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells. Scand J Immunol (2001) 1.07
Effects of some immunosuppressive procedures on myasthenia gravis. Ann N Y Acad Sci (1976) 1.04
Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol (1997) 1.02
Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulation (2000) 1.02
A monoclonal anti-idiotypic antibody against anti-receptor antibodies from myasthenic sera. Eur J Immunol (1982) 1.02
Autoantibodies against oxidized low density lipoproteins (oxLDL): characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of oxLDL. Clin Exp Immunol (1995) 1.01
T cell receptor (TCR) V gene usage in patients with systemic necrotizing vasculitis. Clin Exp Immunol (1995) 0.98
Antibodies from myasthenic patients that compete with cholinergic agents for binding to nicotinic receptors. Proc Natl Acad Sci U S A (1980) 0.96
Experimental myasthenia in Balb/c mice immunized with rat acetylcholine receptor from rat denervated muscle. Proc Natl Acad Sci U S A (1976) 0.96
Two SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravis. J Intern Med (2008) 0.96
Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood (1995) 0.94
Follow-up study of muscle function in children of mothers with myasthenia gravis during pregnancy. J Child Neurol (1992) 0.94
An automated turbidimetric immunoassay for plasma proteins. Scand J Clin Lab Invest (1980) 0.94
Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol (1996) 0.93
Properties and serum levels of specific populations of anti-acetylcholine receptor antibodies in myasthenia gravis. Ann N Y Acad Sci (1981) 0.93
A clinical and immunological study of a myasthenia gravis patient treated with infliximab. Acta Neurol Scand (2007) 0.93
Polymorphisms in IL-1beta and IL-1 receptor antagonist genes are associated with myasthenia gravis. J Neuroimmunol (1998) 0.92
Oligoclonal IgG bands in cerebrospinal fluid. Principles for demonstration and interpretation based on findings in 1114 neurological patients. Arch Neurol (1987) 0.92
Expression of CTLA-4 by human monocytes. Scand J Immunol (2002) 0.92
Intrathymic pathogenesis of myasthenia gravis: transient expression of acetylcholine receptors on thymus-derived myogenic cells. Eur J Immunol (1978) 0.91
Expanded T cell populations in patients with Wegener's granulomatosis: characteristics and correlates with disease activity. J Clin Immunol (1998) 0.91
Beta 2-adrenergic receptor antibodies in myasthenia gravis. J Autoimmun (1992) 0.91
Periductal lymphocytic infiltrates in salivary glands in myasthenia gravis patients lacking Sjögren's syndrome. Clin Exp Immunol (1986) 0.91
Acetylcholine-receptor antibodies in cerebrospinal fluid of patients with myasthenia gravis. Lancet (1977) 0.90
Anti-cardiolipin antibodies and circulating immune complexes in type 1 diabetes mellitus: increased prevalence and relation to vascular complications. Clin Exp Immunol (1999) 0.90
Monoclonal antibodies directed against the neurotransmitter binding site of nicotinic acetylcholine receptor. FEBS Lett (1980) 0.89
The human acetylcholine receptor antibody: studies of kinetic and biochemical properties and the reaction with anti-idiotypic antibodies. Ann N Y Acad Sci (1981) 0.89
Newborn infants to myasthenic mothers: a clinical study and an investigation of acetylcholine receptor antibodies in 17 children. Neurology (1983) 0.89
Mononuclear leukocytes exposed to oxidized low density lipoprotein secrete a factor that stimulates endothelial cells to express adhesion molecules. Atherosclerosis (1993) 0.89
Genetic association of Ctla-4 to myasthenia gravis with thymoma. J Neuroimmunol (1998) 0.88
Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests. Br J Haematol (1995) 0.88
Human monoclonal anti-idiotypic antibodies. I. Establishment of immortalized cell lines from a tumor patient treated with mouse monoclonal antibodies. J Immunol (1988) 0.88
Myasthenia gravis after bone-marrow transplantation. Evidence for a donor origin. N Engl J Med (1983) 0.88
A bias in the alphabeta T cell receptor variable region gene usage in Takayasu's arteritis. Clin Exp Immunol (1997) 0.87
Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand (1998) 0.87
T-cell stimulation induced by idiotypes on monoclonal immunoglobulins in patients with monoclonal gammopathies. Scand J Immunol (1993) 0.87
T-cell expansions with conserved T-cell receptor beta chain motifs in the peripheral blood of HLA-DRB1*0401 positive patients with necrotizing vasculitis. Blood (1998) 0.86
Thymoma-specific antibodies in sera from patients with myasthenia gravis demonstrated by indirect haemagglutination. J Neuroimmunol (1981) 0.86
Antibodies against human cholinergic receptor proteins in patients with myasthenia gravis: Studies during immunosuppressive treatment. Preliminary report. Acta Med Scand (1977) 0.86
Abnormal T-cell expansion and V-gene usage in myasthenia gravis patients. Scand J Immunol (1991) 0.85
The clinical significance of HAMA in patients treated with mouse monoclonal antibodies. Cell Biophys (1994) 0.85
CDS1 and promoter single nucleotide polymorphisms of the CTLA-4 gene in human myasthenia gravis. Genes Immun (2002) 0.85
Anti-idiotypic antibodies, acetylcholine receptor antibodies and disturbed neuromuscular function in healthy relatives to patients with myasthenia gravis. J Neuroimmunol (1985) 0.85
Polymorphisms in CTLA-4 but not tumor necrosis factor-alpha or interleukin 1beta genes are associated with Wegener's granulomatosis. J Rheumatol (2000) 0.84
Antibodies to acetylcholine receptor in patients with thymoma but without myasthenia gravis. Neurology (1980) 0.84
Antibodies against beta1 and beta2 adrenergic receptors in myasthenia gravis. J Neuroimmunol (1998) 0.84
Defective T lymphocyte function in nonthymectomized patients with myasthenia gravis. Clin Immunol Immunopathol (1991) 0.84
Acetylcholine receptor-reactive T cells in myasthenia gravis: evidence for the involvement of different subpopulations of T helper cells. J Neuroimmunol (1994) 0.83
Idiotype-induced T cell stimulation requires antigen presentation in association with HLA-DR molecules. Clin Exp Immunol (1996) 0.83
Study of two different subpopulations of anti-acetylcholine receptor antibodies in a rabbit with experimental auto-immune myasthenia gravis. Eur J Immunol (1977) 0.83
Human monoclonal immunoglobulins that bind the human acetylcholine receptor. Eur J Immunol (1987) 0.83
Binding properties and subclass distribution of anti-acetylcholine receptor antibodies in myasthenia gravis. J Neuroimmunol (1981) 0.83
Increased uptake of acetylcholine-receptor antibody at motor endplate in myasthenic exacerbation. Lancet (1978) 0.83
Central nervous-system involvement in experimental autoimmune myasthenia gravis. Lancet (1977) 0.83
Establishment of idiotype bearing B-lymphocyte clones from a patient with monoclonal gammopathy. Blood (1991) 0.83
[Antibodies against nicotine-like acetylcholine receptors of central nervous system and muscles in epileptics with IgA deficiency]. Schweiz Med Wochenschr (1978) 0.83
beta2 Adrenoceptor gene single nucleotide polymorphisms are associated with rheumatoid arthritis in northern Sweden. Ann Rheum Dis (2004) 0.82
Immunoglobulins in myasthenia gravis. Kinetic properties of the acetylcholine-receptor antibody studied during lymph drainage. Clin Exp Immunol (1978) 0.82
Human muscle acetylcholine receptor reactive T and B lymphocytes in the peripheral blood of patients with myasthenia gravis. J Neuroimmunol (1993) 0.82
Tumour necrosis factor-alpha polymorphism and secretion in myasthenia gravis. J Neuroimmunol (1999) 0.82
Autoantibodies against cardiolipin and endothelial cells in Takayasu's arteritis: prevalence and isotype distribution. Br J Rheumatol (1997) 0.82
Rapid improvement of myasthenia gravis after plasma exchange. Ann Neurol (1982) 0.82
Treatment of myasthenia gravis with anti-CD4 antibody: improvement correlates to decreased T-cell autoreactivity. Neurology (1994) 0.82
Pharmacokinetics of the mouse monoclonal antibody 17-1A in cancer patients receiving various treatment schedules. Cancer Res (1990) 0.82
Autoantibodies against oxidatively modified LDL do not constitute a risk factor for stroke: a nested case-control study. Stroke (1999) 0.81
Specific binding to isolated acetylcholine receptor of a synthetic peptide duplicating the sequence of the presumed active center of a lethal toxin from snake venom. J Biol Chem (1982) 0.81
Encephalopathy, peripheral neuropathy, dysautonomia, myasthenia gravis, malignant thymoma, and antiacetylcholine receptor antibodies in the CSF. Eur Neurol (1983) 0.81
beta2-adrenergic receptor gene single-nucleotide polymorphisms are associated with rheumatoid arthritis in northern Sweden. Scand J Rheumatol (2004) 0.81
Idiotype- and anti-idiotype-reactive T lymphocytes in myasthenia gravis. Evidence for the involvement of different subpopulations of T helper lymphocytes. J Immunol (1994) 0.81
Anti-idiotypic antibodies in patients with monoclonal gammopathies: relation to the tumour load. Br J Haematol (1991) 0.81
Prevalence of antibodies to cardiolipin in chronic ITP and reactivity with platelet membranes. Eur J Haematol (1996) 0.81
Cerebrospinal fluid and blood lymphocyte subpopulations following subarachnoid haemorrhage. Br J Neurosurg (1996) 0.80
Acetylcholine receptor antibodies and anti-idiotypic antibodies produced in blood lymphocyte cultures from patients with myasthenia gravis. Scand J Immunol (1986) 0.80
Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis. Rheumatology (Oxford) (2002) 0.80
Purification and chemical characterization of melittin and acetylated derivatives. Biochim Biophys Acta (1980) 0.80
Neuromuscular safety margin: genetical, immunological and electrophysiological determinants in relatives of myasthenic patients: a preliminary report. Ann N Y Acad Sci (1981) 0.80
Agalactosyl IgG and antibody specificity in rheumatoid arthritis, tuberculosis, systemic lupus erythematosus and myasthenia gravis. Autoimmunity (1995) 0.80